Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

CNS penetrant small molecule pan-histone deacetylase (HDAC) inhibitor designed to treat progressive neurofibromatosis type 2 (NF2)-mutated meningiomas The program halts will shrink Recursion’s ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

which is a good thing because there is little prospect of Recursion delivering any drug approvals within the next three years, given its most advanced program has only reached the Phase 1/2 stage.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

The REC-994 program involved resynthesis ... Recursion's platform. Recursion has specifically highlighted Exscientia’s precision chemistry design and small molecule automated synthesis capabilities.

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

We recently published a list of 8 Best Small-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ ...

is the first designed to be reversible and CNS penetrant for small-cell lung cancer Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new ...